Aardvark Therapeutics, Inc. Common Stock (AARD) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Aardvark Therapeutics, Inc. Common Stock (AARD) Earnings Overview
As of July 8, 2026, Aardvark Therapeutics, Inc. Common Stock (AARD) reported trailing twelve-month net income of -$70M, reflecting -177.9% year-over-year growth. The company earned $-3.20 per diluted share over the past four quarters.
Looking at the long-term picture, AARD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2023.
Aardvark Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RYTM (-$204M net income, -103.6% margin), VNDA (-$240M net income, -102.0% margin), IMVT (-$506M net income), AARD has comparable earnings metrics. Compare AARD vs RYTM →
AARD Earnings vs Peers
Earnings metrics vs comparable public companies
AARD Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$58M | -179.7% | -$63M | $-2.64 | - | - |
| 2024 | -$21M | -185.6% | -$23M | $-0.95 | - | - |
| 2023 | -$7M | +46.9% | -$7M | $-0.34 | - | - |
| 2022 | -$14M | - | -$11M | $-0.63 | - | - |
Download Data
Export AARD earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AARD — Frequently Asked Questions
Quick answers to the most common questions about buying AARD stock.
What is AARD earnings per share (EPS)?
AARD trailing twelve-month (TTM) diluted EPS is $-3.20, reflecting -177.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Aardvark Therapeutics, Inc. Common Stock's net income?
Aardvark Therapeutics, Inc. Common Stock (AARD) trailing twelve-month net income is $-70M as of 2025. Earnings declined -177.9% year-over-year.
Is AARD profitable?
AARD is not currently profitable on a TTM basis, reporting a net loss of $-70M. Net margin is N/A. Investors should monitor for a return to profitability.
What is AARD's earnings growth rate?
AARD compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are AARD's profit margins?
Aardvark Therapeutics, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -221.5%.
Is AARD growing earnings?
AARD earnings are declining — EPS fell -177.9% year-over-year. TTM net income dropped to $-70M. This contrasts with the 5-year CAGR of N/A.
What was AARD's best earnings year?
Aardvark Therapeutics, Inc. Common Stock's highest annual net income on record is $-7M, achieved in fiscal year 2023. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were AARD's earnings last quarter?
AARD's most recent reported quarter was Q1 2026. Net income was $-22M with diluted EPS of $-0.99. For a full breakdown of all quarters, see the quarterly earnings table on this page.